Boston, Massachusetts, United States, August 2025 – Lee Schwartz has been appointed as Sr. Director, Human Resources at Crescent Biopharma, a biopharmaceutical company dedicated to developing next-generation oncology therapies. In this new role, Schwartz will oversee HR strategy, talent management, and organizational development to support Crescent’s vision of advancing transformative treatments for cancer patients.
Most recently, Lee Schwartz served at Vor Bio for nearly four years, progressing from Director, Human Resources Business Partner to Senior Director, HRBP. In this capacity, she partnered with business leaders to strengthen organizational culture, align HR strategy with business objectives, and drive employee engagement across the biotech company’s global operations.
Before joining Vor Bio, she was Associate Director, People and Culture at Magenta Therapeutics, where she played a key role in shaping HR programs, performance management, and talent development strategies to support the company’s growth in cell and gene therapy.
Earlier, Schwartz worked with Karyopharm Therapeutics Inc. as Associate Director, HR Business Partner, building frameworks to support workforce development, employee relations, and leadership engagement. Prior to this, she spent three years at Intarcia Therapeutics, Inc. as Sr. HR Business Partner, where she focused on talent strategies in support of R&D and commercial operations.
Schwartz also built a strong foundation during his long tenure at Idenix Pharmaceuticals, Inc. (later acquired by Merck & Co.). Over more than 13 years, she advanced through multiple roles from Administrative Assistant in R&D to Human Resources Specialist, leading employee onboarding, HRIS implementations, benefits management, and employee relations. Her early professional experiences included roles at Brigham and Women’s Hospital as a Practice Administrator and at Imagitas (MYMOVE) as an Administrative Associate.
About Crescent Biopharma
Crescent Biopharma is a pioneering oncology company focused on developing next-generation therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) aimed at treating a wide range of solid tumors. By leveraging multiple modalities and proven targets, Crescent is committed to rapidly advancing transformative therapies as both single agents and in combination regimens, with the vision of becoming a global leader in oncology innovation.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
